Benlysta FDA Approval History
Last updated by Judith Stewart, BPharm on July 27, 2022.
FDA Approved: Yes (First approved March 10, 2011)
Brand name: Benlysta
Generic name: belimumab
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Lupus, Lupus Nephritis
Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor for the treatment of active systemic lupus erythematosus (SLE) and active lupus nephritis.
Benlysta is indicated for the treatment of:
- patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy;
- patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.
Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Use of Benlysta is not recommended in this situation.
Development timeline for Benlysta
| Date | Article |
|---|
| Jul 27, 2022 | Approval GSK Announces US FDA Approval of Benlysta (belimumab) for Pediatric Patients with Active Lupus Nephritis |
| Dec 17, 2020 | Approval FDA Approves GSK’s Benlysta as the First Medicine for Adult Patients with Active Lupus Nephritis in the US |
| Apr 26, 2019 | Approval GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above |
| Jul 21, 2017 | Approval GSK Receives FDA Approval for a New Self-Injectable Formulation of Benlysta (belimumab) for Systemic Lupus Erythematosus |
| Mar 10, 2011 | Approval FDA Approves Benlysta to Treat Lupus |
| Dec 6, 2010 | GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta PDUFA target date to 10th March 2011 |
| Nov 17, 2010 | Human Genome Sciences and GlaxoSmithKline Announce Vote of FDA Advisory Committee to Recommend Approval of Benlysta for Systemic Lupus Erythematosus |
| Aug 19, 2010 | Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for Benlysta (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus |
| Jul 13, 2010 | Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for Benlysta, a Potential New Treatment for Systemic Lupus Erythematosus |
| Jun 10, 2010 | Human Genome Sciences Announces Submission of Biologics License Application to FDA for Benlysta (belimumab) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
